A new cut point for Unfavorable Intermediate-Risk patients

The GPS assay stratifies unfavorable intermediate-risk patients into two distinct groups with highly differing long-term outcomes1


Unfavorable Intermediate-Risk Patients


GPS 40 wedge

orange person

May be candidates for less aggressive treatment

grey person

May be candidates for more aggressive treatment

 

The Oncotype DX GPS Test for Unfavorable Intermediate Risk Prostate Cancer

See how men with unfavorable intermediate-risk prostate cancer can be stratified into two distinct groups with highly differing long-term outcomes. Use the GPS assay to make informed treatment decisions based on a patient’s genomic risk.

SEE ELIGIBILITY CRITERIA

 


Additional Resources


Download UIR Report Overview PDF


Download Cullen Urology 2020 PDF

REFERENCES

  1. Cullen et al. Urology. 2020.

Stay in Touch

Have questions? We're here to help.

 Contact Us
Copyright © 2004- Genomic Health, Inc. All Rights Reserved.
In the US and certain other jurisdictions, Genomic Health, Oncotype, Oncotype DX, Oncotype IQ, Oncotype MAP, Breast Recurrence Score, Recurrence Score, DCIS Score, Colon Recurrence Score, Genomic Prostate Score, GPS, AR-V7 Nucleus Detect, Pass It On: Until Every Woman Knows, and Making Cancer Care Smarter are trademarks of Genomic Health, Inc. Exact Sciences is a trademark of Exact Sciences Corporation.
Making cancer care smarter.™
X

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.